Skip to main content

Sickle Cell Disease clinical trials at UCSF
4 in progress, 1 open to new patients

  • Allogeneic SCT of CordIn™, in Patients With Hemoglobinopathies

    open to eligible people ages 2–25

    CordIn™ is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic UCB cells. The overall study objectives are to evaluate the safety and efficacy of CordIn™.

    Oakland, California and other locations

  • Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias

    Sorry, accepting new patients by invitation only

    This is a long-term follow-up to an earlier study, LA38-0411. Its purpose is to gather more information about the safety and efficacy of deferiprone in patients with sickle cell disease or other anemias who suffer from iron overload caused by regular blood transfusions.

    Oakland, California and other locations

  • Study of Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation

    Sorry, in progress, not accepting new patients

    Fludarabine is a chemotherapy drug used extensively in bone marrow transplantation. The goal of this study is to determine what causes some children to have different drug concentrations of fludarabine in their bodies and if drug levels are related to whether or not a child experiences severe side-effects during their bone marrow transplant. The hypothesis is that clinical and genetic factors cause changes in fludarabine drug levels in pediatric bone marrow transplant patients and that high levels may cause severe side-effects.

    San Francisco, California

  • Vaporized Cannabis for Chronic Pain Associated With Sickle Cell Disease

    Sorry, in progress, not accepting new patients

    Our primary objective is to assess whether inhaling vaporized cannabis ameliorates chronic pain in patients with sickle cell disease (SCD). As these patients will all be on chronic opioid analgesics, the investigators will also assess the possible synergistic affect between inhaled cannabis and opioids. The investigators will also assess the clinical safety of the concomitant use of cannabinoids and these opioids in patients with SCD by monitoring the short-term side effects associated with combined therapy. Finally, the investigators will evaluate the short-term effects of inhaled cannabis on markers of inflammation and disease progression in patients with SCD. Hypotheses are as follows: 1. Inhaled cannabis will significantly reduce chronic pain in patients with SCD. 2. Inhaled cannabis will significantly alter the short-term side effects experienced by patients who take opioids for SCD. 3. Inhaled cannabis will significantly alter markers of inflammation and disease progression in patients with SCD compared to placebo.

    San Francisco, California